National drug pricing regulator fixes retail value of 36 formulations

Representative Image

National drug pricing regulator NPPA has fixed the prices of 36 formulations, including those used for treatment of cancer, diabetes, infections, asthma, seizures, inflammation and pain, among others.

In a notification, the National Pharmaceutical Pricing Authority (NPPA) said it has fixed retail prices of 22 formulations and has revised ceiling price of 14 formulations.

Among the formulations whose ceiling prices have been revised include Budesonide inhalation used for preventing symptoms of asthma and Gentamicin injection used for treatment of bacterial infections.

The formulations whose retail prices have been fixed include Trastuzumab injection indicated for treatment of metastatic breast cancer and gastric cancer and Metformin plus Gliclazide tablets used for treatment of type 2 diabetes, among others.

NPPA fixes ceiling and retail prices of essential medicines of Schedule I under the Drugs (Prices Control) Order (DPCO) 2013.

It also monitors annual price increase for these and the non-scheduled drugs.

Set up in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of DPCO and monitoring of prices of controlled and non-scheduled medicines.

It also administers Pharma Sahi Dam and Pharma Jan Samadhan platforms for information on medicine prices and registering public grievances.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel